- Approval to sell three additional Kuida® CBD products focused
on anti-aging, hydration and everyday skin care
- Expands revenue generating Kuida® cosmeceutical portfolio to 10
SKU´s
- First sales expected in Q4 for the newly approved products
- Kuida® portfolio first INVIMA-approved branded CBD beauty
product in Colombia
TORONTO, Sept. 25, 2019 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:
KHRNF), (Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America, announced today
that the Company has received approval from INVIMA, Colombia's health agency, to sell 3 additional
Kuida® CBD skin care products. This expands on the 7 products
currently available at retail and online in Colombia, with first sales of the newly
approved product expected in Q4.
Kuida®, the first consumer brand of Khiron's wellness business
unit, brings the benefits of cannabidiol (CBD) to a comprehensive
portfolio of skin and body care products for women. Kuida® was
launched in Q4 2018 and is now widely available in
Colombia through large retailers,
wholesalers and online channels, including Cafam, Fedco, Grupo
Exito and Farmatodo, as well as educational and experiential pop-up
stores in major cities.
Alvaro Torres, CEO and Director
of Khiron, comments: "The first-to-market strategy for
Kuida® has allowed us to establish a large retail partner
network we can now build on with this expanded product line. Our
educational and experiential programs have helped consumers
integrate Kuida CBD products into their daily beauty regimen, and
with these newly approved products, we are now positioned to
further increase our revenue and market reach in Colombia."
Information on the Kuida® portfolio can be found at:
https://kuidaskincare.com/en/
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found
at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-secures-approval-to-sell-three-more-cbd-wellness-products-300924847.html
SOURCE Khiron Life Sciences Corp.